Suresh S. Ramalingam, MD, FASCO, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive non–small cell lung cancer.
Suresh S. Ramalingam
Advertisement
Articles by Suresh S. Ramalingam
Advertisement
Latest Updated Articles
Dr. Suresh S. Ramalingam on Optimizing Immunotherapies in Lung CancerPublished: August 26th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5